Liver Disease Diagnostics Market By Technique (imaging, laboratory tests, endoscopy, biopsy), By End Use (hospitals, laboratories, others): Global Opportunity Analysis and Industry Forecast, 2021-2031

Liver Disease Diagnostics Market

The liver is one of the most important organs in the human body as it eliminates unwanted substances from the blood, regulates chemical levels in the body, and stores nutrients for all cellular and biological activity. The phrase "liver disease" refers to a wide range of issues that causes the liver to fail to perform its primary function. Hepatitis, cirrhosis, liver cancer, and liver abscess are examples of liver diseases. These liver diseases can be diagnosed at early stages by imaging techniques, laboratory tests, endoscopies, and biopsies. Hence, there is a huge demand by medical professionals for liver disease diagnostics.

Growth of the liver disease diagnostics market size is majorly driven by a surge in the number of patients suffering from liver cancer, a rise in the prevalence of acute and chronic hepatitis B, nonalcohol-related fatty liver disease, Wilson disease, iron in hemochromatosis, and hepatocellular carcinoma. For instance, in April 2022, according to Bristol Myers & Squibb, each year, nearly 1 million people die due to hepatitis B or hepatitis C, globally. The Liver Disease Diagnostics Market Share is witnessing significant growth globally, owing to the rise in the adoption of liver disease diagnostics and visualization systems in healthcare settings, coupled with technological advancements.

An increase in alcohol consumption leads to the death of healthy liver cells and reduces the ability to generate new ones as well as leads to a buildup of fats leading to liver diseases. For instance, according to the National Center for Drug Abuse Statistics 2021, about 34.1% reported binge drinking at least once and 7.0% reported extreme binge drinking. Furthermore, in a survey conducted by the Johns Hopkins University of Maryland Baltimore, about 60.1% of the respondents reported that they increased their alcohol consumption after March 1, 2020. Thus, such a rise in high alcohol consumption is expected to lead to liver disorders and further drive the growth of the market. Hence, these factors boost the growth of the liver disease diagnostics market.

The rise in the number of research institutes globally provides growth opportunities for the market. In addition, growth in patient preference for minimally invasive surgeries, and diagnostic procedures, favorable FDA approvals & reimbursement policies in developed economies, and an increase in alcohol consumption and poor dietary habits boost the growth of the liver disease diagnostics market share.

Liver diseases have increased during the COVID-19 pandemic, owing to an increase in the consumption of alcohol and leading to the growth of the liver disease diagnostic market. For instance, according to the article of springer published in 2021, 10,242 hospital admissions for alcohol-related liver disease or pancreatitis occurred in 257 hospitals during pandemic. Out of the 10,242 hospital admissions, 6371 cases were due to alcohol-related liver disease. Fourteen percent of alcohol-related liver disease cases had alcohol hepatitis, and 72% had alcoholic liver cirrhosis. In addition, the COVID-19 pandemic led to rise in awareness regarding physical, mental, and emotional health. This, in turn, has increased awareness regarding diagnosis of liver diseases and increase in regular checkups by using liver disease diagnostics. Thus, such development is anticipated to bring stabilization and drive the growth of the liver disease diagnostic market during the forecast period. 

On the basis of technique, the laboratory tests segment is expected to witness the highest CAGR during the liver disease diagnostics market forecast period, owing to the rise in the prevalence of chronic liver diseases and an increase in awareness regarding laboratory tests for diagnosis of liver diseases and hepatitis. In addition, the rise in the discovery of new laboratory tests and the increase in demand for laboratory tests drives the growth laboratory tests segment.

On the basis of end-user, the laboratories segment is expected to witness the highest CAGR during the forecast period, owing to an increase in incidences of hepatitis and a rise in awareness regarding the diagnosis of hepatitis at an early stage. The rise in healthcare expenditure also boosts the growth of the laboratories segment in the liver disease diagnostics industry.

Depending on the region, Asia-Pacific Liver Disease Diagnostics Industry is expected to witness the highest CAGR during the forecast period, owing to a surge in the geriatric population that is more prone to diseases and a rise in awareness regarding liver disease diagnostics assisted minimally invasive surgeries.

KEY FINDINGS OF THE STUDY

By technique, the imaging segment held the largest share in the liver disease diagnostics market forecast in 2021.

On the basis of end-user, the hospital's segment held the largest market share in 2021.

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the global Liver Disease Diagnostics Market Analysis from 2021 to 2031 to identify the prevailing global liver disease diagnostics market opportunities.

On the basis of region, North America held the largest market share in 2021.

The report includes an analysis of the regional as well as Liver Disease Diagnostics Market Trends, key players, market segments, technique areas, and market growth strategies.

Overview

The liver disease diagnostics market was valued at $34,520.4 million in 2021 and is estimated to reach $61,962.1 million by 2031, growing at a CAGR of 6.1% from 2022 to 2031. 

The liver is a vital organ of the body and has more than 500 functions and primary functions such as bile production & excretion, as excretion as bilirubin, cholesterol, hormones, and drugs. It fights infection, eliminates toxins, and helps in blood purification. Liver disease comprises a range of complex conditions that affect the liver. Liver dysfunction can be fatal and can cause a variety of acute and chronic disorders, including hepatitis A, hepatitis B, hepatitis C, non-alcoholic fatty liver disease, liver cancer, bile duct cancer, liver cell adenoma, and liver cirrhosis. Liver diseases are caused due to infection (parasites and viruses), chronic alcohol abuse, fat accumulation in the liver, immune system abnormality, and inheritance (hemochromatosis, hyperoxaluria, and Wilson’s disease)

Various techniques are used for the diagnosis of liver diseases such as imaging, laboratory tests, endoscopy, and biopsy. An increase in the use of imaging such as MRI, CT scan, and laboratory for the diagnosis of liver diseases boosts the growth of the liver disease diagnostics market.

Major factors that drive the growth of the liver disease diagnostics market include a rise in technological advancements, and an increase in the prevalence rate of chronic liver diseases such as hepatitis, chronic hepatitis B, chronic hepatitis C, and nonalcohol-related fatty liver disease (NAFLD). In addition, other liver diseases include infiltrative liver disorders (e.g., hepatic sarcoidosis and amyloidosis), alpha-1 antitrypsin deficiency, primary biliary cholangitis, and primary sclerosing cholangitis.

For instance, according to a report by the World Health Organization (WHO) published on June 2022, globally, an estimated 58 million people had chronic hepatitis C virus infection, with around 1.5 million new infections occurring per year. An estimated 3.2 million adolescents and children have chronic hepatitis C infection. Hence, such factors increase the demand for liver disease diagnostics.

However, unfavorable reimbursements, as well as complications such as the dearth of trained physicians & endoscopists, side effects of biopsy, and high costs associated with liver disease diagnostic products, are expected to hamper the market growth. On the contrary, unmet medical demands in developing countries and lucrative opportunities in emerging economies are expected to create immense opportunities for liver disease diagnostics manufacturers worldwide in the future.

Furthermore, the healthcare business is projected to witness growth, owing to a rise in the prevalence of chronic liver diseases, hepatitis, and liver cancer; an increase in R&D investments in drug discovery & development, and a rise in awareness regarding the minimally invasive diagnostic procedure for liver diseases. This is anticipated to offer remunerative opportunities for key players to invest in the market during the forecast period.

The liver disease diagnostics market is segmented on the basis of technique, end user, and region. On the basis of technique, the market is classified into imaging, laboratory tests, endoscopy, and biopsy. Depending on the end user, it is fragmented into hospitals, laboratories, and others. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and the rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major players profiled in the report are Abbott Laboratories, Bio-Rad Laboratories Inc., Cosara Diagnostics Pvt Ltd, Echosens, Fujifilm Holdings Corporation, Meril Life Sciences Pvt. Ltd., Qiagen N.V., Siemens AG, Thermo Fisher Scientific Inc., and Trivitron Healthcare.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the liver disease diagnostics market analysis from 2021 to 2031 to identify the prevailing liver disease diagnostics market opportunities.

Market research is offered along with information related to key drivers, restraints, and opportunities.

Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.

In-depth analysis of the liver disease diagnostics market segmentation assists to determine the prevailing market opportunities.

Major countries in each region are mapped according to their revenue contribution to the global market.

Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

The report includes the analysis of the regional as well as global liver disease diagnostics market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

○ Trivitron Healthcar

Scope of Liver Disease Diagnostics Market Report

1.1.Report description

1.2.Key market segments

1.3.Key benefits to the stakeholders

1.4.Research Methodology

1.4.1.Secondary research

1.4.2.Primary research

1.4.3.Analyst tools and models

2.1.Key findings of the study

2.2.CXO Perspective

3.1.Market definition and scope

3.2.Key findings

3.2.1.Top investment pockets

3.3.Porter’s five forces analysis

3.4.Top player positioning

3.5.Market dynamics

3.5.1.Drivers

3.5.2.Restraints

3.5.3.Opportunities

3.6.COVID-19 Impact Analysis on the market

4.1 Overview

4.1.1 Market size and forecast

4.2 imaging

4.2.1 Key market trends, growth factors and opportunities

4.2.2 Market size and forecast, by region

4.2.3 Market analysis by country

4.3 laboratory tests

4.3.1 Key market trends, growth factors and opportunities

4.3.2 Market size and forecast, by region

4.3.3 Market analysis by country

4.4 endoscopy

4.4.1 Key market trends, growth factors and opportunities

4.4.2 Market size and forecast, by region

4.4.3 Market analysis by country

4.5 biopsy

4.5.1 Key market trends, growth factors and opportunities

4.5.2 Market size and forecast, by region

4.5.3 Market analysis by country

5.1 Overview

5.1.1 Market size and forecast

5.2 hospitals

5.2.1 Key market trends, growth factors and opportunities

5.2.2 Market size and forecast, by region

5.2.3 Market analysis by country

5.3 laboratories

5.3.1 Key market trends, growth factors and opportunities

5.3.2 Market size and forecast, by region

5.3.3 Market analysis by country

5.4 others

5.4.1 Key market trends, growth factors and opportunities

5.4.2 Market size and forecast, by region

5.4.3 Market analysis by country

6.1 Overview

6.1.1 Market size and forecast

6.2 North America

6.2.1 Key trends and opportunities

6.2.2 North America Market size and forecast, by Technique

6.2.3 North America Market size and forecast, by End Use

6.2.4 North America Market size and forecast, by country

6.2.4.1 U.S.

6.2.4.1.1 Market size and forecast, by Technique

6.2.4.1.2 Market size and forecast, by End Use

6.2.4.2 Canada

6.2.4.2.1 Market size and forecast, by Technique

6.2.4.2.2 Market size and forecast, by End Use

6.2.4.3 Mexico

6.2.4.3.1 Market size and forecast, by Technique

6.2.4.3.2 Market size and forecast, by End Use

6.3 Europe

6.3.1 Key trends and opportunities

6.3.2 Europe Market size and forecast, by Technique

6.3.3 Europe Market size and forecast, by End Use

6.3.4 Europe Market size and forecast, by country

6.3.4.1 Germany

6.3.4.1.1 Market size and forecast, by Technique

6.3.4.1.2 Market size and forecast, by End Use

6.3.4.2 France

6.3.4.2.1 Market size and forecast, by Technique

6.3.4.2.2 Market size and forecast, by End Use

6.3.4.3 UK

6.3.4.3.1 Market size and forecast, by Technique

6.3.4.3.2 Market size and forecast, by End Use

6.3.4.4 Italy

6.3.4.4.1 Market size and forecast, by Technique

6.3.4.4.2 Market size and forecast, by End Use

6.3.4.5 Spain

6.3.4.5.1 Market size and forecast, by Technique

6.3.4.5.2 Market size and forecast, by End Use

6.3.4.6 Rest of Europe

6.3.4.6.1 Market size and forecast, by Technique

6.3.4.6.2 Market size and forecast, by End Use

6.4 Asia-Pacific

6.4.1 Key trends and opportunities

6.4.2 Asia-Pacific Market size and forecast, by Technique

6.4.3 Asia-Pacific Market size and forecast, by End Use

6.4.4 Asia-Pacific Market size and forecast, by country

6.4.4.1 China

6.4.4.1.1 Market size and forecast, by Technique

6.4.4.1.2 Market size and forecast, by End Use

6.4.4.2 Japan

6.4.4.2.1 Market size and forecast, by Technique

6.4.4.2.2 Market size and forecast, by End Use

6.4.4.3 India

6.4.4.3.1 Market size and forecast, by Technique

6.4.4.3.2 Market size and forecast, by End Use

6.4.4.4 South Korea

6.4.4.4.1 Market size and forecast, by Technique

6.4.4.4.2 Market size and forecast, by End Use

6.4.4.5 Australia

6.4.4.5.1 Market size and forecast, by Technique

6.4.4.5.2 Market size and forecast, by End Use

6.4.4.6 Rest of Asia-Pacific

6.4.4.6.1 Market size and forecast, by Technique

6.4.4.6.2 Market size and forecast, by End Use

6.5 LAMEA

6.5.1 Key trends and opportunities

6.5.2 LAMEA Market size and forecast, by Technique

6.5.3 LAMEA Market size and forecast, by End Use

6.5.4 LAMEA Market size and forecast, by country

6.5.4.1 Brazil

6.5.4.1.1 Market size and forecast, by Technique

6.5.4.1.2 Market size and forecast, by End Use

6.5.4.2 Saudi Arabia

6.5.4.2.1 Market size and forecast, by Technique

6.5.4.2.2 Market size and forecast, by End Use

6.5.4.3 South Africa

6.5.4.3.1 Market size and forecast, by Technique

6.5.4.3.2 Market size and forecast, by End Use

6.5.4.4 Rest of LAMEA

6.5.4.4.1 Market size and forecast, by Technique

6.5.4.4.2 Market size and forecast, by End Use

7.1. Introduction

7.2. Top winning strategies

7.3. Product Mapping of Top 10 Player

7.4. Competitive Dashboard

7.5. Competitive Heatmap

7.6. Key developments

8.1 Abbott Laboratories

8.1.1 Company overview

8.1.2 Company snapshot

8.1.3 Operating business segments

8.1.4 Product portfolio

8.1.5 Business performance

8.1.6 Key strategic moves and developments

8.2 Bio-Rad Laboratories Inc.

8.2.1 Company overview

8.2.2 Company snapshot

8.2.3 Operating business segments

8.2.4 Product portfolio

8.2.5 Business performance

8.2.6 Key strategic moves and developments

8.3 Cosara Diagnostics Pvt Ltd

8.3.1 Company overview

8.3.2 Company snapshot

8.3.3 Operating business segments

8.3.4 Product portfolio

8.3.5 Business performance

8.3.6 Key strategic moves and developments

8.4 Echosens

8.4.1 Company overview

8.4.2 Company snapshot

8.4.3 Operating business segments

8.4.4 Product portfolio

8.4.5 Business performance

8.4.6 Key strategic moves and developments

8.5 Meril Life Sciences Pvt. Ltd.

8.5.1 Company overview

8.5.2 Company snapshot

8.5.3 Operating business segments

8.5.4 Product portfolio

8.5.5 Business performance

8.5.6 Key strategic moves and developments

8.6 PerkinElmer

8.6.1 Company overview

8.6.2 Company snapshot

8.6.3 Operating business segments

8.6.4 Product portfolio

8.6.5 Business performance

8.6.6 Key strategic moves and developments

8.7 Qiagen N.V.

8.7.1 Company overview

8.7.2 Company snapshot

8.7.3 Operating business segments

8.7.4 Product portfolio

8.7.5 Business performance

8.7.6 Key strategic moves and developments

8.8 Siemen’s AG

8.8.1 Company overview

8.8.2 Company snapshot

8.8.3 Operating business segments

8.8.4 Product portfolio

8.8.5 Business performance

8.8.6 Key strategic moves and developments

8.9 Thermo Fisher Scientific Inc.

8.9.1 Company overview

8.9.2 Company snapshot

8.9.3 Operating business segments

8.9.4 Product portfolio

8.9.5 Business performance

8.9.6 Key strategic moves and developments

8.10 Trivitron Healthcare

8.10.1 Company overview

8.10.2 Company snapshot

8.10.3 Operating business segments

8.10.4 Product portfolio

8.10.5 Business performance

8.10.6 Key strategic moves and development

LIST OF TABLES

TABLE 1. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)

TABLE 2. LIVER DISEASE DIAGNOSTICS MARKET, FOR IMAGING, BY REGION, 2021-2031 ($MILLION)

TABLE 3. LIVER DISEASE DIAGNOSTICS MARKET FOR IMAGING, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 4. LIVER DISEASE DIAGNOSTICS MARKET, FOR LABORATORY TESTS, BY REGION, 2021-2031 ($MILLION)

TABLE 5. LIVER DISEASE DIAGNOSTICS MARKET FOR LABORATORY TESTS, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 6. LIVER DISEASE DIAGNOSTICS MARKET, FOR ENDOSCOPY, BY REGION, 2021-2031 ($MILLION)

TABLE 7. LIVER DISEASE DIAGNOSTICS MARKET FOR ENDOSCOPY, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 8. LIVER DISEASE DIAGNOSTICS MARKET, FOR BIOPSY, BY REGION, 2021-2031 ($MILLION)

TABLE 9. LIVER DISEASE DIAGNOSTICS MARKET FOR BIOPSY, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 10. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)

TABLE 11. LIVER DISEASE DIAGNOSTICS MARKET, FOR HOSPITALS, BY REGION, 2021-2031 ($MILLION)

TABLE 12. LIVER DISEASE DIAGNOSTICS MARKET FOR HOSPITALS, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 13. LIVER DISEASE DIAGNOSTICS MARKET, FOR LABORATORIES, BY REGION, 2021-2031 ($MILLION)

TABLE 14. LIVER DISEASE DIAGNOSTICS MARKET FOR LABORATORIES, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 15. LIVER DISEASE DIAGNOSTICS MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)

TABLE 16. LIVER DISEASE DIAGNOSTICS MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 17. LIVER DISEASE DIAGNOSTICS MARKET, BY REGION, 2021-2031 ($MILLION)

TABLE 18. NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)

TABLE 19. NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)

TABLE 20. NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 21. U.S. LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)

TABLE 22. U.S. LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)

TABLE 23. CANADA LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)

TABLE 24. CANADA LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)

TABLE 25. MEXICO LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)

TABLE 26. MEXICO LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)

TABLE 27. EUROPE LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)

TABLE 28. EUROPE LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)

TABLE 29. EUROPE LIVER DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 30. GERMANY LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)

TABLE 31. GERMANY LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)

TABLE 32. FRANCE LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)

TABLE 33. FRANCE LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)

TABLE 34. UK LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)

TABLE 35. UK LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)

TABLE 36. ITALY LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)

TABLE 37. ITALY LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)

TABLE 38. SPAIN LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)

TABLE 39. SPAIN LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)

TABLE 40. REST OF EUROPE LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)

TABLE 41. REST OF EUROPE LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)

TABLE 42. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)

TABLE 43. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)

TABLE 44. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 45. CHINA LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)

TABLE 46. CHINA LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)

TABLE 47. JAPAN LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)

TABLE 48. JAPAN LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)

TABLE 49. INDIA LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)

TABLE 50. INDIA LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)

TABLE 51. SOUTH KOREA LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)

TABLE 52. SOUTH KOREA LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)

TABLE 53. AUSTRALIA LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)

TABLE 54. AUSTRALIA LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)

TABLE 55. REST OF ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)

TABLE 56. REST OF ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)

TABLE 57. LAMEA LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)

TABLE 58. LAMEA LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)

TABLE 59. LAMEA LIVER DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 60. BRAZIL LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)

TABLE 61. BRAZIL LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)

TABLE 62. SAUDI ARABIA LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)

TABLE 63. SAUDI ARABIA LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)

TABLE 64. SOUTH AFRICA LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)

TABLE 65. SOUTH AFRICA LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)

TABLE 66. REST OF LAMEA LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)

TABLE 67. REST OF LAMEA LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)

TABLE 68.ABBOTT LABORATORIES: COMPANY SNAPSHOT

TABLE 69.ABBOTT LABORATORIES: OPERATING SEGMENTS

TABLE 70.ABBOTT LABORATORIES: PRODUCT PORTFOLIO

TABLE 71.ABBOTT LABORATORIES: NET SALES,

TABLE 72.ABBOTT LABORATORIES: KEY STRATERGIES

TABLE 73.BIO-RAD LABORATORIES INC.: COMPANY SNAPSHOT

TABLE 74.BIO-RAD LABORATORIES INC.: OPERATING SEGMENTS

TABLE 75.BIO-RAD LABORATORIES INC.: PRODUCT PORTFOLIO

TABLE 76.BIO-RAD LABORATORIES INC.: NET SALES,

TABLE 77.BIO-RAD LABORATORIES INC.: KEY STRATERGIES

TABLE 78.COSARA DIAGNOSTICS PVT LTD: COMPANY SNAPSHOT

TABLE 79.COSARA DIAGNOSTICS PVT LTD: OPERATING SEGMENTS

TABLE 80.COSARA DIAGNOSTICS PVT LTD: PRODUCT PORTFOLIO

TABLE 81.COSARA DIAGNOSTICS PVT LTD: NET SALES,

TABLE 82.COSARA DIAGNOSTICS PVT LTD: KEY STRATERGIES

TABLE 83.ECHOSENS: COMPANY SNAPSHOT

TABLE 84.ECHOSENS: OPERATING SEGMENTS

TABLE 85.ECHOSENS: PRODUCT PORTFOLIO

TABLE 86.ECHOSENS: NET SALES,

TABLE 87.ECHOSENS: KEY STRATERGIES

TABLE 88.MERIL LIFE SCIENCES PVT. LTD.: COMPANY SNAPSHOT

TABLE 89.MERIL LIFE SCIENCES PVT. LTD.: OPERATING SEGMENTS

TABLE 90.MERIL LIFE SCIENCES PVT. LTD.: PRODUCT PORTFOLIO

TABLE 91.MERIL LIFE SCIENCES PVT. LTD.: NET SALES,

TABLE 92.MERIL LIFE SCIENCES PVT. LTD.: KEY STRATERGIES

TABLE 93.PERKINELMER: COMPANY SNAPSHOT

TABLE 94.PERKINELMER: OPERATING SEGMENTS

TABLE 95.PERKINELMER: PRODUCT PORTFOLIO

TABLE 96.PERKINELMER: NET SALES,

TABLE 97.PERKINELMER: KEY STRATERGIES

TABLE 98.QIAGEN N.V.: COMPANY SNAPSHOT

TABLE 99.QIAGEN N.V.: OPERATING SEGMENTS

TABLE 100.QIAGEN N.V.: PRODUCT PORTFOLIO

TABLE 101.QIAGEN N.V.: NET SALES,

TABLE 102.QIAGEN N.V.: KEY STRATERGIES

TABLE 103.SIEMEN’S AG: COMPANY SNAPSHOT

TABLE 104.SIEMEN’S AG: OPERATING SEGMENTS

TABLE 105.SIEMEN’S AG: PRODUCT PORTFOLIO

TABLE 106.SIEMEN’S AG: NET SALES,

TABLE 107.SIEMEN’S AG: KEY STRATERGIES

TABLE 108.THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT

TABLE 109.THERMO FISHER SCIENTIFIC INC.: OPERATING SEGMENTS

TABLE 110.THERMO FISHER SCIENTIFIC INC.: PRODUCT PORTFOLIO

TABLE 111.THERMO FISHER SCIENTIFIC INC.: NET SALES,

TABLE 112.THERMO FISHER SCIENTIFIC INC.: KEY STRATERGIES

TABLE 113.TRIVITRON HEALTHCARE: COMPANY SNAPSHOT

TABLE 114.TRIVITRON HEALTHCARE: OPERATING SEGMENTS

TABLE 115.TRIVITRON HEALTHCARE: PRODUCT PORTFOLIO

TABLE 116.TRIVITRON HEALTHCARE: NET SALES,

TABLE 117.TRIVITRON HEALTHCARE: KEY STRATERGIES LIST OF FIGURES

FIGURE 1.LIVER DISEASE DIAGNOSTICS MARKET SEGMENTATION

FIGURE 2.LIVER DISEASE DIAGNOSTICS MARKET,2021-2031

FIGURE 3.LIVER DISEASE DIAGNOSTICS MARKET,2021-2031

FIGURE 4. TOP INVESTMENT POCKETS, BY REGION

FIGURE 5.PORTER FIVE-1

FIGURE 6.PORTER FIVE-2

FIGURE 7.PORTER FIVE-3

FIGURE 8.PORTER FIVE-4

FIGURE 9.PORTER FIVE-5

FIGURE 10.TOP PLAYER POSITIONING

FIGURE 11.LIVER DISEASE DIAGNOSTICS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES

FIGURE 12.LIVER DISEASE DIAGNOSTICS MARKET,BY TECHNIQUE,2021(%)

FIGURE 13.COMPARATIVE SHARE ANALYSIS OF IMAGING LIVER DISEASE DIAGNOSTICS MARKET,2021-2031(%)

FIGURE 14.COMPARATIVE SHARE ANALYSIS OF LABORATORY TESTS LIVER DISEASE DIAGNOSTICS MARKET,2021-2031(%)

FIGURE 15.COMPARATIVE SHARE ANALYSIS OF ENDOSCOPY LIVER DISEASE DIAGNOSTICS MARKET,2021-2031(%)

FIGURE 16.COMPARATIVE SHARE ANALYSIS OF BIOPSY LIVER DISEASE DIAGNOSTICS MARKET,2021-2031(%)

FIGURE 17.LIVER DISEASE DIAGNOSTICS MARKET,BY END USE,2021(%)

FIGURE 18.COMPARATIVE SHARE ANALYSIS OF HOSPITALS LIVER DISEASE DIAGNOSTICS MARKET,2021-2031(%)

FIGURE 19.COMPARATIVE SHARE ANALYSIS OF LABORATORIES LIVER DISEASE DIAGNOSTICS MARKET,2021-2031(%)

FIGURE 20.COMPARATIVE SHARE ANALYSIS OF OTHERS LIVER DISEASE DIAGNOSTICS MARKET,2021-2031(%)

FIGURE 21.LIVER DISEASE DIAGNOSTICS MARKET BY REGION,2021

FIGURE 22.U.S. LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)

FIGURE 23.CANADA LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)

FIGURE 24.MEXICO LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)

FIGURE 25.GERMANY LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)

FIGURE 26.FRANCE LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)

FIGURE 27.UK LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)

FIGURE 28.ITALY LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)

FIGURE 29.SPAIN LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)

FIGURE 30.REST OF EUROPE LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)

FIGURE 31.CHINA LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)

FIGURE 32.JAPAN LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)

FIGURE 33.INDIA LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)

FIGURE 34.SOUTH KOREA LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)

FIGURE 35.AUSTRALIA LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)

FIGURE 36.REST OF ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)

FIGURE 37.BRAZIL LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)

FIGURE 38.SAUDI ARABIA LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)

FIGURE 39.SOUTH AFRICA LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)

FIGURE 40.REST OF LAMEA LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)

FIGURE 41. TOP WINNING STRATEGIES, BY YEAR

FIGURE 42. TOP WINNING STRATEGIES, BY DEVELOPMENT

FIGURE 43. TOP WINNING STRATEGIES, BY COMPANY

FIGURE 44.PRODUCT MAPPING OF TOP 10 PLAYERS

FIGURE 45.COMPETITIVE DASHBOARD

FIGURE 46.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS

FIGURE 47.ABBOTT LABORATORIES.: NET SALES ,($MILLION)

FIGURE 48.BIO-RAD LABORATORIES INC..: NET SALES ,($MILLION)

FIGURE 49.COSARA DIAGNOSTICS PVT LTD.: NET SALES ,($MILLION)

FIGURE 50.ECHOSENS.: NET SALES ,($MILLION)

FIGURE 51.MERIL LIFE SCIENCES PVT. LTD..: NET SALES ,($MILLION)

FIGURE 52.PERKINELMER.: NET SALES ,($MILLION)

FIGURE 53.QIAGEN N.V..: NET SALES ,($MILLION)

FIGURE 54.SIEMEN’S AG.: NET SALES ,($MILLION)

FIGURE 55.THERMO FISHER SCIENTIFIC INC..: NET SALES ,($MILLION)

FIGURE 56.TRIVITRON HEALTHCARE.: NET SALES ,($MILLION